𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab

✍ Scribed by Edmund Cauza; Marita Spak; Karla Cauza; Ursula Hanusch-Enserer; Attila Dunky; Ernst Wagner

Publisher
Springer
Year
2002
Tongue
English
Weight
230 KB
Volume
22
Category
Article
ISSN
0172-8172

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiangiogenic effects of anti–tumor nec
Antiangiogenic effects of anti–tumor necrosis factor α therapy with infliximab in psoriatic arthritis
✍ Juan D. Cañete; José L. Pablos; Raimon Sanmartí; Carmen Mallofré; Sara Marsal; J 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 1 views

## Abstract ## Objective Neovascularization, with an increased number of synovial vessels with a characteristic morphology, seems to contribute to the progression of psoriatic arthritis (PsA). Accordingly, angiogenesis may be an important therapeutic target in PsA. The aim of this study was to ana

Treatment of psoriatic arthritis with an
Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
✍ A.L.J. Ogilvie; C. Antoni; C. Dechant; B. Manger; J.R. Kalden; G. Schuler; M. Lü 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB

## Background: In inflamed skin, keratinocytes and inflammatory cells both produce large amounts of tumour necrosis factor (tnf) -alpha, a cytokine with broad effects that are relevant to inflammation. blockade of this proinflammatory cytokine by a monoclonal anti-tnf-alpha antibody might be effect

Individualized monitoring of drug bioava
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b

Treatment with tumor necrosis factor inh
Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis
✍ Lotta Ljung; Julia F. Simard; Lennart Jacobsson; Solbritt Rantapää-Dahlqvist; Jo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 3 views

## Abstract ## Objective Rheumatoid arthritis (RA) is associated with an increased risk of ischemic heart disease, in both early and established RA. Data on the risk of ischemic heart disease in relation to therapy with tumor necrosis factor (TNF) antagonists (anti‐TNF) are conflicting in patients